Neuropilin as a biomarker for bevacizumab combination therapies
作者： Dorothee Foernzler , Paul Delmar , Stefan Scherer
DOI:
关键词:
摘要: The present invention provides methods for improving treatment effect in a patient suffering from gastric cancer, particular, adenocarcinoma of the stomach or gastro-esophageal junction ("GEJ"), by with bevacizumab (Avastin®) combination chemotherapy regimen determining expression level neuropilin relative to control determined patients ("GEJ"). improved may be overall survival progression free survival. further assessing sensitivity responsiveness regimen,
lens.org 参考文章(9)
Heinz-Josef Lenz, Genetic markers for predicting responsiveness to combination therapy ,(2011)
Andreas Pircher, Wolfgang Hilbe, Isabel Heidegger, Joachim Drevs, André Tichelli, Michael Medinger, Biomarkers in Tumor Angiogenesis and Anti-Angiogenic Therapy International Journal of Molecular Sciences. ,vol. 12, pp. 7077- 7099 ,(2011) , 10.3390/IJMS12107077
Donna E Hansel, Robert E Wilentz, Charles J Yeo, Richard D Schulick, Elizabeth Montgomery, Anirban Maitra, Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract. The American Journal of Surgical Pathology. ,vol. 28, pp. 347- 356 ,(2004) , 10.1097/00000478-200403000-00007
B.F. El-Rayes, M. Zalupski, T. Bekai-Saab, L.K. Heilbrun, N. Hammad, B. Patel, S. Urba, A.F. Shields, U. Vaishampayan, S. Dawson, K. Almhanna, D. Smith, P.A. Philip, A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers Annals of Oncology. ,vol. 21, pp. 1999- 2004 ,(2010) , 10.1093/ANNONC/MDQ065
Atsushi Ohtsu, Manish A. Shah, Eric Van Cutsem, Sun Young Rha, Akira Sawaki, Sook Ryun Park, Ho Yeong Lim, Yasuhide Yamada, Jian Wu, Bernd Langer, Michal Starnawski, Yoon-Koo Kang, Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Journal of Clinical Oncology. ,vol. 29, pp. 3968- 3976 ,(2011) , 10.1200/JCO.2011.36.2236
Manish A. Shah, Ramesh K. Ramanathan, David H. Ilson, Alissa Levnor, David D'Adamo, Eileen O'Reilly, Archie Tse, Robin Trocola, Lawrence Schwartz, Marinela Capanu, Gary K. Schwartz, David P. Kelsen, Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Journal of Clinical Oncology. ,vol. 24, pp. 5201- 5206 ,(2006) , 10.1200/JCO.2006.08.0887
Y. Kang, A. Ohtsu, E. Van Cutsem, S. Y. Rha, A. Sawaki, S. Park, H. Lim, J. Wu, B. Langer, M. A. Shah, AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). Journal of Clinical Oncology. ,vol. 28, ,(2010) , 10.1200/JCO.2010.28.18_SUPPL.LBA4007
Dorothee Foernzler, Paul Delmar, Stefan Scherer, Tumor tissue based biomarkers for bevacizumab combination therapies ,(2011)
Lee You Mie, USAGE OF NEUROPILIN2 FOR DIAGNOSIS AND TREATMENT OF GASTRIC CANCER ,(2010)